Phase I/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

We investigated the combination of midostaurin and azacitidine (AZA) in patients with AML and high risk MDS. Patients received AZA 75 mg/m(2) on days 1–7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8–21 during the first cycle...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Hematol
Asıl Yazarlar: Strati, Paolo, Kantarjian, Hagop, Ravandi, Farhad, Nazha, Aziz, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Estrov, Zeev, Garcia-Manero, Guillermo, Konopleva, Marina, Rajkhowa, Trivikram, Durand, Menda, Andreeff, Michael, Levis, Mark, Cortes, Jorge
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4376596/
https://ncbi.nlm.nih.gov/pubmed/25530214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23924
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller